Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Harvoni Most Prescribed Drug at Acute Hospitals in October-December
April 27, 2016
- Chugai, Hiroshima Univ. Spinoff Join Hands in Cartilage Regeneration
April 26, 2016
- Boehringer Japan’s Ethical Drug Sales Tick Up 2% in 2015
April 26, 2016
- Novartis Seeks Add’l Indications for Ilaris in Japan
April 26, 2016
- Novartis Looks to Harness Big Data for Indication Expansions: Global Medical Chief
April 26, 2016
- MSD, Sanofi to End RotaTeq, Heptavax Copromotion in Japan
April 25, 2016
- Janssen Files Simponi for Ulcerative Colitis in Japan
April 25, 2016
- Kaketsuken Continues to Suspend Production as Huge Damages Found
April 22, 2016
- Novo Nordisk’s Japan Sales Log Record 89 Billion Yen on Tresiba, Victoza
April 22, 2016
- Around 140 Clinical Trials of Nucleic Acid Drugs Underway Worldwide, with Cancer, Neuropathy, and Myopathy as Main Targets
April 22, 2016
- Mylan Japan Management, Labor Union Remain at Odds over Sales Rep Layoff
April 21, 2016
- Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use
April 21, 2016
- Ajinomoto Pulls Out from JV with Yoshindo as EA Pharma Launched
April 21, 2016
- MSD’s Hep C Drugs Get Priority Review Status in Japan
April 20, 2016
- Biogen Files MS Treatment Dimethyl Fumarate in Japan
April 20, 2016
- FunPep, Morishita Jintan Sign MOU to Commercialize Products Containing Antibacterial Peptide
April 19, 2016
- AbbVie Starts Japan PIIb/III Study of Selective JAK1 Inhibitor in RA Patients
April 19, 2016
- Heptares, Kymab Tie Up for Joint Research on Cancer Immunotherapy
April 19, 2016
- Wholesalers Say Drug Distributions in Quake-Hit Kumamoto More or Less Stable
April 19, 2016
- Sanwa Kagaku’s Kumamoto Factory Shuts Down after Quake
April 18, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…